GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (LTS:0HFR) » Definitions » Shiller PE Ratio

Anavex Life Sciences (LTS:0HFR) Shiller PE Ratio : (As of May. 24, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Anavex Life Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anavex Life Sciences Shiller PE Ratio Historical Data

The historical data trend for Anavex Life Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Shiller PE Ratio Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anavex Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anavex Life Sciences's Shiller PE Ratio

For the Biotechnology subindustry, Anavex Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Shiller PE Ratio falls into.



Anavex Life Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Anavex Life Sciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Anavex Life Sciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.13/131.7762*131.7762
=-0.130

Current CPI (Mar. 2024) = 131.7762.

Anavex Life Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.120 100.560 -0.157
201409 -0.860 100.428 -1.128
201412 -0.060 99.070 -0.080
201503 -0.120 99.621 -0.159
201506 -0.220 100.684 -0.288
201509 -0.167 100.392 -0.219
201512 -0.120 99.792 -0.158
201603 -0.060 100.470 -0.079
201606 -0.060 101.688 -0.078
201609 -0.180 101.861 -0.233
201612 -0.080 101.863 -0.103
201703 -0.040 102.862 -0.051
201706 -0.090 103.349 -0.115
201709 -0.120 104.136 -0.152
201712 -0.090 104.011 -0.114
201803 -0.110 105.290 -0.138
201806 -0.060 106.317 -0.074
201809 -0.130 106.507 -0.161
201812 -0.150 105.998 -0.186
201903 -0.150 107.251 -0.184
201906 -0.130 108.070 -0.159
201909 -0.110 108.329 -0.134
201912 -0.120 108.420 -0.146
202003 -0.120 108.902 -0.145
202006 -0.110 108.767 -0.133
202009 -0.100 109.815 -0.120
202012 -0.120 109.897 -0.144
202103 -0.120 111.754 -0.141
202106 -0.140 114.631 -0.161
202109 -0.150 115.734 -0.171
202112 -0.140 117.630 -0.157
202203 -0.140 121.301 -0.152
202206 -0.160 125.017 -0.169
202209 -0.180 125.227 -0.189
202212 -0.170 125.222 -0.179
202303 -0.170 127.348 -0.176
202306 -0.140 128.729 -0.143
202309 -0.130 129.860 -0.132
202312 -0.110 129.419 -0.112
202403 -0.130 131.776 -0.130

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anavex Life Sciences  (LTS:0HFR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Anavex Life Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (LTS:0HFR) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (LTS:0HFR) Headlines

No Headlines